Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Not Yet RecruitingNCT07695142
What this trial is testing

Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor (Phase 1)
Haisco Pharmaceutical Group Co., Ltd. 275
Testing effectiveness (Phase 2)Active Not RecruitingNCT04837209
What this trial is testing

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Massachusetts General Hospital 32
Not applicableUnknownNCT03927599
What this trial is testing

Advanced Refractory Solid Tumors With TP53 Mutations Register Study

Who this might be right for
Solid Tumor, Adult
Tianjin Medical University Second Hospital 100
Large-scale testing (Phase 3)Ended earlyNCT04729387
What this trial is testing

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Who this might be right for
Ovarian Cancer
Novartis Pharmaceuticals 358
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Testing effectiveness (Phase 2)Looking for participantsNCT05898399
What this trial is testing

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Who this might be right for
Advanced Solid TumorMetastatic Solid Tumor
Artios Pharma Ltd 181
Early research (Phase 1)WithdrawnNCT03575078
What this trial is testing

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Who this might be right for
Lymphoma
University of Texas Southwestern Medical Center
Early research (Phase 1)Ended earlyNCT04586335
What this trial is testing

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Who this might be right for
Ovarian CancerBreast CancerSolid Tumor+2 more
Haihe Biopharma Co., Ltd. 24
Early research (Phase 1)WithdrawnNCT05807126
What this trial is testing

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT02890355
What this trial is testing

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage IV Pancreatic Cancer AJCC v6 and v7
National Cancer Institute (NCI) 123
Testing effectiveness (Phase 2)UnknownNCT05407584
What this trial is testing

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Who this might be right for
PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Yonsei University 56
Testing effectiveness (Phase 2)Ended earlyNCT04538378
What this trial is testing

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

Who this might be right for
EGFR-Mutated Non-Small-Cell Lung CarcinomaSmall Cell/Neuroendocrine
National Cancer Institute (NCI) 4
Early research (Phase 1)Ended earlyNCT00272415
What this trial is testing

Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma

Who this might be right for
Melanoma
Genentech, Inc. 39
Early research (Phase 1)Study completedNCT01345357
What this trial is testing

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

Who this might be right for
Solid Tumors or Mantle Cell Lymphoma
Cephalon 24
Testing effectiveness (Phase 2)Study completedNCT03326193
What this trial is testing

Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 105
Testing effectiveness (Phase 2)Looking for participantsNCT05700721
What this trial is testing

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Who this might be right for
Brain Metastases
M.D. Anderson Cancer Center 120
Testing effectiveness (Phase 2)Looking for participantsNCT03990896
What this trial is testing

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Who this might be right for
Breast Cancer
Massachusetts General Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT05538091
What this trial is testing

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaPARP Inhibitor+1 more
Ronald Buckanovich 48
Early research (Phase 1)Looking for participantsNCT05870423
What this trial is testing

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Who this might be right for
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy
Erasmus Medical Center 24
Early research (Phase 1)Study completedNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Next Page